Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is…
In Conversation
The Pharmaceutical Services Division has been around since 1951, what have been the major shifts in its objectives since then? When the pharmacy service came into…
One of the key factors for the growth in the pharmaceutical market has been the increasing professionalism of healthcare in Malaysia. How does the MMA contribute…
Before joining Nycomed you spent a year working at the Drug Control Authority (DCA). What did your regulatory friends say when you told them you were…
When we spoke to Herbert Dittmar of Bayer, he said that there were no specific challenges in Malaysia that could not be found elsewhere. How do…
Would you give our readers an insight into the government’s attempts to foster a better environment for FDI in Malaysia? Over the last year, the significant…
Can you give our readers an outline of Bayer’s background in Malaysia and its current organisational division? Herbert Dittmar (HD): Bayer has been in Malaysia for…
Kebangsaan Malaysia (UKM). Singapore and Taiwan are known for their high level of basic research and their focus on Biotechnology. Philip Yeo, Chairman of Spring Singapore…
Nowadays we can talk of an abundance of information coming from companies like Frost& Sullivan, IMS and even consultancies who are producing their own data. As…
You have worked in the pharmaceutical industry for many years starting with Novartis and you have spent the last eight years working for Lundbeck. What are…
Pharmaceutical Executive is a magazine about executives, their experience and their perspectives on the pharmaceutical industry. You have worked in Australia, Hong Kong and now you…
You spent most of your career in the pharmaceutical industry with Bristol Meyers Squibb and earlier on for NV Organon which you joined in 1998. In…
